文献速递皮肤肿瘤

纳武利尤单抗对比伊匹木单抗治疗晚期黑色素瘤:一项批判性评价

Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal: ORIGINAL ARTICLE: Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377:1345-56.
PubMed 文献 · Br J Dermatol · 2018-06-05

该研究为多国随机对照试验,纳入945例初治晚期黑色素瘤患者,比较纳武利尤单抗联合伊匹木单抗、纳武利尤单抗单药与伊匹木单抗单药。3年总生存率分别为58%、52%和34%,联合组与单药组相比伊匹木单抗组均显著延长总生存期和无进展生存期。

要点

  • 3年总生存率:联合组58%、纳武利尤单抗组52%、伊匹木单抗组34%。
  • 联合组死亡风险比为0.55(95%CI 0.45-0.69;P<0.001),纳武利尤单抗组为0.65(95%CI 0.53-0.80;P<0.001)。
  • 3年无进展生存率:联合组39%、纳武利尤单抗组32%、伊匹木单抗组10%。

核心结论

  • 在晚期黑色素瘤患者中,纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药相比伊匹木单抗单药均显著延长总生存期和无进展生存期。
  • 亚组分析中,含纳武利尤单抗组的生存结局优于伊匹木单抗组。

研究设计与样本

  • 该试验在21个国家的137个中心开展,随机分组(n=945;1:1:1比例),按转移分期、BRAF突变状态和程序性死亡配体1状态分层。
  • 成人患者随机接受以下方案之一:纳武利尤单抗联合伊匹木单抗每3周一次共4剂,随后纳武利尤单抗每2周一次;纳武利尤单抗每2周一次联合安慰剂;或伊匹木单抗每3周一次共4剂联合安慰剂。
  • 治疗持续至疾病进展、不可接受毒性或退出。

主要发现

  • 3年总生存率:纳武利尤单抗联合伊匹木单抗组58%、纳武利尤单抗单药组52%、伊匹木单抗单药组34%。
  • 纳武利尤单抗联合伊匹木单抗组中位总生存期未达到;纳武利尤单抗单药组中位总生存期37.6个月;伊匹木单抗单药组中位总生存期19.9个月。
  • 死亡风险比:纳武利尤单抗联合伊匹木单抗对比伊匹木单抗为0.55(95%CI 0.45-0.69;P<0.001);纳武利尤单抗对比伊匹木单抗为0.65(95%CI 0.53-0.80;P<0.001)。
  • 3年无进展生存率:纳武利尤单抗联合伊匹木单抗组39%、纳武利尤单抗单药组32%、伊匹木单抗单药组10%,两个纳武利尤单抗组的95%CI与伊匹木单抗单药组不重叠。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To show whether either nivolumab in combination with ipilimumab or nivolumab monotherapy vs. ipilimumab monotherapy extends overall survival (OS) or progression-free survival (PFS) in adults with previously untreated, advanced melanoma. SETTING AND DESIGN: The trial was conducted at 137 sites in 21 countries. Randomization (n = 945; 1 : 1 : 1 ratio) was stratified according to metastasis stage, BRAF mutation status and programmed death ligand 1 status. STUDY EXPOSURE: Adults were randomized to one of the following: nivolumab plus ipilimumab every 3 weeks for four doses, followed by nivolumab every 2 weeks; nivolumab every 2 weeks plus placebo; or ipilimumab every 3 weeks for four doses plus placebo. Treatment was continued until progression, unacceptable toxicity or withdrawal. OUTCOMES: OS, PFS and objective response rate were determined. Patients were also assessed for adverse events. The primary end points of interest were OS and PFS, comparing either the nivolumab plus ipilimumab group or the nivolumab-only group with the patients treated with ipilimumab only. RESULTS: At 3 years, the OS rates were 58%, 52% and 34% for the nivolumab plus ipilimumab, the nivolumab monotherapy and the ipilimumab monotherapy groups, respectively. For the nivolumab plus ipilimumab group, the median OS was not reached at the time of analysis. For the nivolumab-only group, the median OS was 37·6 months, and the ipilimumab-only group had a median OS of 19·9 months. The hazard ratio for death was 0·55 [95% confidence interval (CI) 0·45-0·69; P < 0·001] comparing nivolumab plus ipilimumab with ipilimumab, and 0·65 (95% CI 0·53-0·80; P < 0·001) comparing nivolumab with ipilimumab. The PFS rates at 3 years were 39% for the nivolumab plus ipilimumab group, 32% for the nivolumab monotherapy group and 10% for the ipilimumab monotherapy group, with 95% CIs for the two nivolumab groups that did not overlap with that for ipilimumab alone. CONCLUSIONS: Among patients with advanced melanoma, significantly longer OS and PFS occurred with the combination of nivolumab plus ipilimumab or with nivolumab alone compared with ipilimumab alone. Furthermore, survival outcomes favoured the nivolumab-containing groups over the ipilimumab group in subgroup analyses.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Wan MT, Ming ME. Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal: ORIGINAL ARTICLE: Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377:1345-56. Br J Dermatol. 2018. PMID: 29766492. doi:10.1111/bjd.16785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。